A Phase 3 interventional study of Adalimumab and Placebo in Nail Psoriasis and Plaque Psoriasis, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-05-30.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.
Among the 48 studies testing adalimumab in Psoriasis, this one is the 20th largest by enrollment, is one of 2 that started in 2014, is one of 26 in phase 3, and was the 29th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
Mabscale, LLC · Sites in Russian Federation
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ages 4–17
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 27 · Phase 4 11
First in 2003; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 217 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 148 across the 48 interventional studies. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 48 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
79 studies in Psoriasis by AbbVie: 2 open now, 6 under way, 1 of them phase 3. Of 71 finished, 42 (59%) have results posted.
Among the 79 studies in Psoriasis by AbbVie, this one is the 20th largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2014, is one of 31 in phase 3, and was the 28th registered.
AbbVie’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 48 studies testing adalimumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to assess the safety and efficacy of adalimumab in participants with nail psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Period A: ADA 40 mg subcutaneous every other week (sc eow) for 25 weeks starting 1 week after initial loading dose of 80 mg. Period B: Placebo at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
Biological: Adalimumab · Other: Placebo
Period A: Placebo sc eow for 25 weeks. Period B: ADA 80 mg sc at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
Biological: Adalimumab · Other: Placebo
Also known as: ABT-D2E7, Humira
Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26
Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. Investigators assessed each nail abnormality for each of a participant's nails by grading 3 features or groups of features (pitting, onycholysis and oil-drop dyschromia, and crumbling) and noting the presence or absence of 4 features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula). The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement. The mNAPSI 75 response is defined as at least 75% reduction from baseline in mNAPSI.
Time frame: Week 26
For United States (US) Regulatory Purposes: Percentage of Participants With a Physician's Global Assessment of Fingernails (PGA-F) of "Clear" or "Minimal" at Week 26
The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a PGA-F overall global score that met the definition of "clear" (0) or "minimal" (1) with at least a 2-grade improvement relative to Baseline at Week 26.
Time frame: Week 26
Percent Change From Baseline in Total Fingernail Nail Psoriasis Severity Index (NAPSI) Score at Week 26
Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
Time frame: Baseline, Week 26
Percentage of Participants Achieving Total Fingernail mNAPSI Score of 0 at Week 26
Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Time frame: Week 26
Percent Change From Baseline in Nail Psoriasis Pain Numeric Rating Scale (NRS) at Week 26
An NRS was used to capture a participant's self-reporting of her/his worst fingernail pain and average fingernail pain due to fingernail psoriasis. The participant rated the severity of fingernail pain over the past 7 days on a scale from 0 indicating no pain, to 10 indicating severe pain. A negative change from Baseline indicates improvement.
Time frame: Baseline, Week 26
Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26
Participants were asked to rate the impact of their fingernail psoriasis on their ability to perform physical tasks (eg, typing, housework, buttoning a shirt or blouse, picking up coins from a table, tying shoes, yard work, etc.) over the past 7 days on a scale of 0 indicating no impact on ability to perform physical tasks, to 10 indicating severe impact on ability to perform physical tasks. A negative change from Baseline indicates improvement.
Time frame: Baseline, Week 26
Percentage of Participants With at Least 50% Improvement in the Scalp Component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI) at Week 26
The range of possible scores was 0 to 20 for scalp psoriasis, with a score of 0 indicating absence of psoriasis. A decrease in B-SNIPI score indicates improvement. Data presents the percentage of participants achieving 50% improvement in the scalp component of the B-SNIPI among participants with Baseline scalp score of ≥ 6.
Time frame: Baseline, Week 26
Percentage of Participants Achieving "Clear" or "Minimal" in Nail Bed Component of the PGA-F at Week 26
The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a nail bed component of the PGA-F that met definition of "clear" (0) or "minimal" (1) among those with a Baseline nail bed component of "moderate" or "worse."
Time frame: Week 26
Percentage of Participants Achieving "Clear" or "Minimal" in Nail Matrix Component of the PGA-F At Week 26
The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a nail matrix component of the PGA-F that met definition of "clear" (0) or "minimal" (1) among those with a Baseline nail matrix component of "moderate" or "worse."
Time frame: Week 26
Percentage of Participants Achieving Target Fingernail mNAPSI Score of 0 at Week 26
The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Time frame: Week 26
Percentage of Participants Achieving Target Fingernail mNAPSI Score of ≤ 2 at Week 26
The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Time frame: Week 26
Percentage of Participants Achieving Total Fingernail mNAPSI Score of ≤ 2 at Week 26
Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Time frame: Week 26
Change From Baseline in Target Fingernail mNAPSI Score at Week 26
The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Time frame: Baseline, Week 26
Percent Change From Baseline in Target Fingernail mNAPSI Score at Week 26
The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Time frame: Baseline, Week 26
Change From Baseline in Total Fingernail mNAPSI Score at Week 26
Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Time frame: Baseline, Week 26
Percent Change From Baseline in Total Fingernail mNAPSI Score at Week 26
Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Time frame: Baseline, Week 26
Percentage of Participants Achieving Total Fingernail NAPSI Score of 0 at Week 26
Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
Time frame: Week 26
Percentage of Participants Achieving Target Fingernail NAPSI Score of 0 at Week 26
The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
Time frame: Week 26
Change From Baseline in Target Fingernail NAPSI Score at Week 26
The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
Time frame: Baseline, Week 26
Percent Change From Baseline in Target Fingernail NAPSI Score at Week 26
The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
Time frame: Baseline, Week 26
Change From Baseline in Total Fingernail NAPSI Score at Week 26
Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
Time frame: Baseline, Week 26
Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 26
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. A decrease in PASI score indicates improvement.
Time frame: Baseline, Week 26
Percent Change From Baseline in PASI Score at Week 26
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. A decrease in PASI score indicates improvement.
Time frame: Baseline, Week 26
Percentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. PASI-75, 50, 90, and 100 responses are the percentage of participants with a Baseline PASI score ≥ 5 who achieved at least a 75%, 50%, 90%, or 100% reduction (improvement), respectively, from Baseline in PASI score at Week 26. A 100% reduction was considered complete clearance of psoriasis. Data presents the percentage of participants achieving PASI 75/50/90/100 responses at Week 26 among participants with a Baseline PASI score ≥ 5.
Time frame: Week 26
Percentage of Participants Achieving Physician's Global Assessment of Skin Psoriasis (PGA-S) "Clear" or "Minimal" at Week 26
The PGA-S is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was assessed, with 0 indicating cleared and 5 indicating severe. A decrease in PGA-S score indicates improvement. Data present the percentage of participants achieving a PGA-S of "clear" (0) or "minimal" (1) with at least a 2-grade improvement relative to Baseline at Week 26.
Time frame: Week 26
Percentage of Participants Achieving PGA-S of "Clear" at Week 26
The PGA-S is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was assessed, with 0 indicating cleared and 5 indicating severe. A decrease in PGA-S score indicates improvement. Data present the percentage of participants achieving a PGA-S of "clear" (0) with at least a 2-grade improvement relative to Baseline at Week 26.
Time frame: Week 26
Percentage of Participants Achieving 50% Improvement in the Inverse Psoriasis Component of the B-SNIPI at Week 26
The range of possible B-SNIPI scores was 0 to 20 for inverse psoriasis, with a score of 0 indicating absence of psoriasis and a score of 20 indicating most severe psoriasis. A decrease in B-SNIPI score indicates improvement. Data presents the percentage of participants achieving 50% improvement in the inverse component of the B-SNIPI among participants with a Baseline inverse psoriasis score of ≥ 6.
Time frame: Week 26
Change From Baseline in Total Body Surface Area (BSA) at Week 26
BSA affected by psoriasis was measured by the physician selecting the participant's right or left hand as the measuring device. For purposes of clinical estimation, the total surface of the palm plus 5 digits was to be assumed to be approximately equivalent to 1% BSA. Measurement of the total area of involvement by the physician was aided by imagining if scattered plaques were moved so that they were next to each other and then estimated the total area involved. A decrease in BSA affected by psoriasis indicates improvement.
Time frame: Baseline, Week 26
Percent Change From Baseline in Total BSA at Week 26
BSA affected by psoriasis was measured by the physician selecting the participant's right or left hand as the measuring device. For purposes of clinical estimation, the total surface of the palm plus 5 digits was to be assumed to be approximately equivalent to 1% BSA. Measurement of the total area of involvement by the physician was aided by imagining if scattered plaques were moved so that they were next to each other and then estimated the total area involved. A decrease in BSA affected by psoriasis indicates improvement.
Time frame: Baseline, Week 26
Percent Change From Baseline in Nail Psoriasis Pain NRS at Week 26
An NRS was used to capture a participant's self-reporting of her/his worst fingernail pain and average fingernail pain due to fingernail psoriasis. The participant rated the severity of fingernail pain over the past 7 days on a scale from 0 indicating no pain, to 10 indicating severe pain. A negative change from Baseline indicates improvement.
Time frame: Baseline, Week 26
Percent Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26
Participants were asked to rate the impact of their fingernail psoriasis on their ability to perform physical tasks (eg, typing, housework, buttoning a shirt or blouse, picking up coins from a table, tying shoes, yard work, etc.) over the past 7 days on a scale of 0 indicating no impact on ability to perform physical tasks, to 10 indicating severe impact on ability to perform physical tasks. A negative change from Baseline indicates improvement.
Time frame: Baseline, Week 26
Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL) at Week 26
Participants rated specific impacts of fingernail psoriasis on various aspects of their QoL over the past 7 days on a 5-point scale, with 0 indicating not at all, and 4 indicating very impactful. A participant's overall global score was the mean of all items and could range from 0 to 4, with 0 indicating no impact and 4 indicating most impact. A decrease in NAPPA QoL score indicates improvement.
Time frame: Baseline, Week 26
Percent Change From Baseline in Nail Assessment in NAPPA QoL at Week 26
Participants rated specific impacts of fingernail psoriasis on various aspects of their QoL over the past 7 days on a 5-point scale, with 0 indicating not at all, and 4 indicating very impactful. A participant's overall global score was the mean of all items and could range from 0 to 4, with 0 indicating no impact and 4 indicating most impact. A decrease in NAPPA QoL score indicates improvement.
Time frame: Baseline, Week 26
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 26
Participants assessed symptoms and impacts of dermatologic diseases on their QoL over the past 7 days, with 0 indicating not at all, and 3 indicating very much. The range of possible DLQI scores was 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement.
Time frame: Baseline, Week 26
Percentage of Participants Achieving DLQI of 0 and 0/1 at Week 26
Participants assessed symptoms and impacts of dermatologic diseases on their QoL over the past 7 days, with 0 indicating not at all, and 3 indicating very much. The range of possible DLQI scores was 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement. Data presents the percentage of participants with a score of 0 (no effect) or 1 (little effect) at Week 26.
Time frame: Week 26
Change From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26
The WPAI: NPSO assessed impact of fingernail psoriasis on work productivity and non-work activity limitation. Participants were asked during the past 7 days, how many hours did you miss from work because of problems associated with your fingernail psoriasis (absenteeism), during the past seven days, how many hours did you miss from work because of any other reason, such as vacation, holidays, time off to participate in this study (presenteeism), how much did your fingernail psoriasis affect your productivity while you were working (overall work impairment), and much did your fingernail psoriasis affect your ability to do your regular daily activities, other than work at a job (activity impairment). Answers were rated on an 11-point scale, with 0 indicating "fingernail psoriasis had no effect on this" and 10 indicating "fingernail psoriasis completely prevented me from this." A decrease in the WPAI:NPSO score indicates improvement.
Time frame: Baseline, Week 26
Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Health State Assessment at Week 26
The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the subject's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. A unique EQ-5D-5L health state is defined by combining the numeric level scores for each of the 5 dimensions and the total score is normalized from -0.594 to 1.000, with higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement.
Time frame: Baseline, Week 26
Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 26
The EQ-5D VAS records the participant's self-rated health status on a vertical graduated scale from 0 to 100, with 0 indicating the worst imaginable health state and 100 indicating the best imaginable health state. An increase in EQ-5D-5L VAS score indicates improvement.
Time frame: Baseline, Week 26
Change From Baseline in Hospital Anxiety Depression Scale (HADS) at Week 26
Participants rated their anxiety and depression over the past 7 days at Week 26. The range of possible scores was 0 to 21, with a score of 0 indicating absence of anxiety and depression and 21 indicating the most severe anxiety and depression. A decrease in HADS score indicates improvement.
Time frame: Baseline, Week 26
Percentage of Participants With a New Diagnosis of Psoriatic Arthritis (PsA) During the Study
The percentage of participants with a new diagnosis of PsA (ie, with an adverse event of PsA) during the study, among participants without PsA at Baseline.
Time frame: up to Week 26
Change From Baseline in Nail Psoriasis Quality of Life (Nail PsQoL) Score at Week 26
Participants were asked how their fingernail psoriasis impacted their overall quality of life over the past 7 days on an 11-point scale, with 0 indicating no impact, and 10 indicating severe impact. A negative change from Baseline indicates improvement.
Time frame: Baseline, Week 26
| Milestone | Placebo | Adalimumab EOW |
|---|---|---|
| Started | 108 | 109 |
| Completed | 94 | 94 |
| Not completed | 14 | 15 |
| Withdrew: Adverse event | 3 | 5 |
| Withdrew: Withdrawal by subject | 3 | 4 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Lack of efficacy | 2 | 1 |
| Withdrew: Other | 3 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Required alternative/prohibited therapy | 0 | 1 |
| Milestone | Placebo | Adalimumab EOW |
|---|---|---|
| Started | 94 | 94 |
| Completed | 81 | 87 |
| Not completed | 13 | 7 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Lack of efficacy | 6 | 4 |
| Withdrew: Other | 4 | 0 |
| Withdrew: Required alternative/prohibited therapy | 0 | 2 |
Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. Investigators assessed each nail abnormality for each of a participant's nails by grading 3 features or groups of features (pitting, onycholysis and oil-drop dyschromia, and crumbling) and noting the presence or absence of 4 features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula). The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement. The mNAPSI 75 response is defined as at least 75% reduction from baseline in mNAPSI.
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26 | 3.4 | 46.6 |
The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a PGA-F overall global score that met the definition of "clear" (0) or "minimal" (1) with at least a 2-grade improvement relative to Baseline at Week 26.
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| For United States (US) Regulatory Purposes: Percentage of Participants With a Physician's Global Assessment of Fingernails (PGA-F) of "Clear" or "Minimal" at Week 26 | 6.9 | 48.9 |
Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
| percent change | Placebo | Adalimumab EOW |
|---|---|---|
| Percent Change From Baseline in Total Fingernail Nail Psoriasis Severity Index (NAPSI) Score at Week 26 | -11.5 ± 3.19 | -56.2 ± 3.12 |
Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| Percentage of Participants Achieving Total Fingernail mNAPSI Score of 0 at Week 26 | 0.0 | 6.6 |
An NRS was used to capture a participant's self-reporting of her/his worst fingernail pain and average fingernail pain due to fingernail psoriasis. The participant rated the severity of fingernail pain over the past 7 days on a scale from 0 indicating no pain, to 10 indicating severe pain. A negative change from Baseline indicates improvement.
| percent change | Placebo | Adalimumab EOW |
|---|---|---|
| Percent Change From Baseline in Nail Psoriasis Pain Numeric Rating Scale (NRS) at Week 26 | -1.1 ± 0.24 | -3.7 ± 0.23 |
Participants were asked to rate the impact of their fingernail psoriasis on their ability to perform physical tasks (eg, typing, housework, buttoning a shirt or blouse, picking up coins from a table, tying shoes, yard work, etc.) over the past 7 days on a scale of 0 indicating no impact on ability to perform physical tasks, to 10 indicating severe impact on ability to perform physical tasks. A negative change from Baseline indicates improvement.
| units on a scale | Placebo | Adalimumab EOW |
|---|---|---|
| Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26 | -0.8 ± 0.24 | -3.7 ± 0.25 |
The range of possible scores was 0 to 20 for scalp psoriasis, with a score of 0 indicating absence of psoriasis. A decrease in B-SNIPI score indicates improvement. Data presents the percentage of participants achieving 50% improvement in the scalp component of the B-SNIPI among participants with Baseline scalp score of ≥ 6.
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| Percentage of Participants With at Least 50% Improvement in the Scalp Component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI) at Week 26 | 0.4 | 58.3 |
The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a nail bed component of the PGA-F that met definition of "clear" (0) or "minimal" (1) among those with a Baseline nail bed component of "moderate" or "worse."
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| Percentage of Participants Achieving "Clear" or "Minimal" in Nail Bed Component of the PGA-F at Week 26 | 8.2 | 51.4 |
The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a nail matrix component of the PGA-F that met definition of "clear" (0) or "minimal" (1) among those with a Baseline nail matrix component of "moderate" or "worse."
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| Percentage of Participants Achieving "Clear" or "Minimal" in Nail Matrix Component of the PGA-F At Week 26 | 8.5 | 53.3 |
The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| Percentage of Participants Achieving Target Fingernail mNAPSI Score of 0 at Week 26 | 1.3 | 19.9 |
The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| Percentage of Participants Achieving Target Fingernail mNAPSI Score of ≤ 2 at Week 26 | 7.3 | 43.3 |
Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| Percentage of Participants Achieving Total Fingernail mNAPSI Score of ≤ 2 at Week 26 | 0.2 | 13.4 |
The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
| units on a scale | Placebo | Adalimumab EOW |
|---|---|---|
| Change From Baseline in Target Fingernail mNAPSI Score at Week 26 | -2.1 ± 0.27 | -5.7 ± 0.27 |
The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
| percent change | Placebo | Adalimumab EOW |
|---|---|---|
| Percent Change From Baseline in Target Fingernail mNAPSI Score at Week 26 | -23.0 ± 2.92 | -61.9 ± 2.91 |
Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
| units on a scale | Placebo | Adalimumab EOW |
|---|---|---|
| Change From Baseline in Total Fingernail mNAPSI Score at Week 26 | -7.5 ± 1.78 | -36.1 ± 1.80 |
Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
| percent change | Placebo | Adalimumab EOW |
|---|---|---|
| Percent Change From Baseline in Total Fingernail mNAPSI Score at Week 26 | -13.2 ± 3.06 | -63.3 ± 3.02 |
Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| Percentage of Participants Achieving Total Fingernail NAPSI Score of 0 at Week 26 | 0.0 | 7.5 |
The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| Percentage of Participants Achieving Target Fingernail NAPSI Score of 0 at Week 26 | 2.4 | 20.8 |
The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
| units on a scale | Placebo | Adalimumab EOW |
|---|---|---|
| Change From Baseline in Target Fingernail NAPSI Score at Week 26 | -1.1 ± 0.21 | -3.6 ± 0.21 |
The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
| percent change | Placebo | Adalimumab EOW |
|---|---|---|
| Percent Change From Baseline in Target Fingernail NAPSI Score at Week 26 | -14.4 ± 3.50 | -54.6 ± 3.47 |
Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.
| units on a scale | Placebo | Adalimumab EOW |
|---|---|---|
| Change From Baseline in Total Fingernail NAPSI Score at Week 26 | -6.7 ± 1.51 | -26.2 ± 1.47 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. A decrease in PASI score indicates improvement.
| units on a scale | Placebo | Adalimumab EOW |
|---|---|---|
| Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 26 | -0.9 ± 0.70 | -9.0 ± 0.70 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. A decrease in PASI score indicates improvement.
| percent change | Placebo | Adalimumab EOW |
|---|---|---|
| Percent Change From Baseline in PASI Score at Week 26 | 2.4 ± 5.77 | -68.7 ± 5.70 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. PASI-75, 50, 90, and 100 responses are the percentage of participants with a Baseline PASI score ≥ 5 who achieved at least a 75%, 50%, 90%, or 100% reduction (improvement), respectively, from Baseline in PASI score at Week 26. A 100% reduction was considered complete clearance of psoriasis. Data presents the percentage of participants achieving PASI 75/50/90/100 responses at Week 26 among participants with a Baseline PASI score ≥ 5.
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| PASI 75 | 13.8 | 64.8 |
| PASI 50 | 25.3 | 77.8 |
| PASI 90 | 7.1 | 48.0 |
| PASI 100 | 2.9 | 29.3 |
The PGA-S is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was assessed, with 0 indicating cleared and 5 indicating severe. A decrease in PGA-S score indicates improvement. Data present the percentage of participants achieving a PGA-S of "clear" (0) or "minimal" (1) with at least a 2-grade improvement relative to Baseline at Week 26.
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| Percentage of Participants Achieving Physician's Global Assessment of Skin Psoriasis (PGA-S) "Clear" or "Minimal" at Week 26 | 11.2 | 63.4 |
The PGA-S is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was assessed, with 0 indicating cleared and 5 indicating severe. A decrease in PGA-S score indicates improvement. Data present the percentage of participants achieving a PGA-S of "clear" (0) with at least a 2-grade improvement relative to Baseline at Week 26.
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| Percentage of Participants Achieving PGA-S of "Clear" at Week 26 | 4.0 | 28.8 |
The range of possible B-SNIPI scores was 0 to 20 for inverse psoriasis, with a score of 0 indicating absence of psoriasis and a score of 20 indicating most severe psoriasis. A decrease in B-SNIPI score indicates improvement. Data presents the percentage of participants achieving 50% improvement in the inverse component of the B-SNIPI among participants with a Baseline inverse psoriasis score of ≥ 6.
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| Percentage of Participants Achieving 50% Improvement in the Inverse Psoriasis Component of the B-SNIPI at Week 26 | 0.5 | 90.8 |
BSA affected by psoriasis was measured by the physician selecting the participant's right or left hand as the measuring device. For purposes of clinical estimation, the total surface of the palm plus 5 digits was to be assumed to be approximately equivalent to 1% BSA. Measurement of the total area of involvement by the physician was aided by imagining if scattered plaques were moved so that they were next to each other and then estimated the total area involved. A decrease in BSA affected by psoriasis indicates improvement.
| percentage of affected BSA | Placebo | Adalimumab EOW |
|---|---|---|
| Change From Baseline in Total Body Surface Area (BSA) at Week 26 | 0.4 ± 1.00 | -10.7 ± 1.00 |
BSA affected by psoriasis was measured by the physician selecting the participant's right or left hand as the measuring device. For purposes of clinical estimation, the total surface of the palm plus 5 digits was to be assumed to be approximately equivalent to 1% BSA. Measurement of the total area of involvement by the physician was aided by imagining if scattered plaques were moved so that they were next to each other and then estimated the total area involved. A decrease in BSA affected by psoriasis indicates improvement.
| percent change | Placebo | Adalimumab EOW |
|---|---|---|
| Percent Change From Baseline in Total BSA at Week 26 | 12.8 ± 6.08 | -67.8 ± 6.01 |
An NRS was used to capture a participant's self-reporting of her/his worst fingernail pain and average fingernail pain due to fingernail psoriasis. The participant rated the severity of fingernail pain over the past 7 days on a scale from 0 indicating no pain, to 10 indicating severe pain. A negative change from Baseline indicates improvement.
| percent change | Placebo | Adalimumab EOW |
|---|---|---|
| Percent Change From Baseline in Nail Psoriasis Pain NRS at Week 26 | -18.0 ± 4.80 | -68.9 ± 4.70 |
Participants were asked to rate the impact of their fingernail psoriasis on their ability to perform physical tasks (eg, typing, housework, buttoning a shirt or blouse, picking up coins from a table, tying shoes, yard work, etc.) over the past 7 days on a scale of 0 indicating no impact on ability to perform physical tasks, to 10 indicating severe impact on ability to perform physical tasks. A negative change from Baseline indicates improvement.
| percent change | Placebo | Adalimumab EOW |
|---|---|---|
| Percent Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26 | -9.9 ± 5.51 | -67.6 ± 5.63 |
Participants rated specific impacts of fingernail psoriasis on various aspects of their QoL over the past 7 days on a 5-point scale, with 0 indicating not at all, and 4 indicating very impactful. A participant's overall global score was the mean of all items and could range from 0 to 4, with 0 indicating no impact and 4 indicating most impact. A decrease in NAPPA QoL score indicates improvement.
| units on a scale | Placebo | Adalimumab EOW |
|---|---|---|
| Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL) at Week 26 | -0.4 ± 0.07 | -1.3 ± 0.07 |
Participants rated specific impacts of fingernail psoriasis on various aspects of their QoL over the past 7 days on a 5-point scale, with 0 indicating not at all, and 4 indicating very impactful. A participant's overall global score was the mean of all items and could range from 0 to 4, with 0 indicating no impact and 4 indicating most impact. A decrease in NAPPA QoL score indicates improvement.
| percent change | Placebo | Adalimumab EOW |
|---|---|---|
| Percent Change From Baseline in Nail Assessment in NAPPA QoL at Week 26 | -11.7 ± 2.24 | -39.5 ± 2.23 |
Participants assessed symptoms and impacts of dermatologic diseases on their QoL over the past 7 days, with 0 indicating not at all, and 3 indicating very much. The range of possible DLQI scores was 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement.
| units on a scale | Placebo | Adalimumab EOW |
|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 26 | -1.9 ± 0.60 | -8.0 ± 0.60 |
Participants assessed symptoms and impacts of dermatologic diseases on their QoL over the past 7 days, with 0 indicating not at all, and 3 indicating very much. The range of possible DLQI scores was 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement. Data presents the percentage of participants with a score of 0 (no effect) or 1 (little effect) at Week 26.
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| DLQI = 0 | 2.5 | 18.2 |
| DLQI = 0/1 | 3.7 | 30.8 |
The WPAI: NPSO assessed impact of fingernail psoriasis on work productivity and non-work activity limitation. Participants were asked during the past 7 days, how many hours did you miss from work because of problems associated with your fingernail psoriasis (absenteeism), during the past seven days, how many hours did you miss from work because of any other reason, such as vacation, holidays, time off to participate in this study (presenteeism), how much did your fingernail psoriasis affect your productivity while you were working (overall work impairment), and much did your fingernail psoriasis affect your ability to do your regular daily activities, other than work at a job (activity impairment). Answers were rated on an 11-point scale, with 0 indicating "fingernail psoriasis had no effect on this" and 10 indicating "fingernail psoriasis completely prevented me from this." A decrease in the WPAI:NPSO score indicates improvement.
| units on a scale | Placebo | Adalimumab EOW |
|---|---|---|
| Absenteeism; n=65, 74 | -1.0 ± 0.73 | -0.3 ± 0.65 |
| Presenteeism; n=70, 77 | -3.4 ± 2.08 | -20.7 ± 2.06 |
| Overall Work impairment; n=65, 74 | -6.2 ± 2.20 | -21.3 ± 2.05 |
| Activity impairment; n=106, 108 | -1.8 ± 2.09 | -23.1 ± 2.18 |
The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the subject's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. A unique EQ-5D-5L health state is defined by combining the numeric level scores for each of the 5 dimensions and the total score is normalized from -0.594 to 1.000, with higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement.
| units on a scale | Placebo | Adalimumab EOW |
|---|---|---|
| Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Health State Assessment at Week 26 | 0.0 ± 0.01 | 0.1 ± 0.01 |
The EQ-5D VAS records the participant's self-rated health status on a vertical graduated scale from 0 to 100, with 0 indicating the worst imaginable health state and 100 indicating the best imaginable health state. An increase in EQ-5D-5L VAS score indicates improvement.
| units on a scale | Placebo | Adalimumab EOW |
|---|---|---|
| Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 26 | -0.1 ± 1.53 | 5.5 ± 1.53 |
Participants rated their anxiety and depression over the past 7 days at Week 26. The range of possible scores was 0 to 21, with a score of 0 indicating absence of anxiety and depression and 21 indicating the most severe anxiety and depression. A decrease in HADS score indicates improvement.
| units on a scale | Placebo | Adalimumab EOW |
|---|---|---|
| HADS anxiety score; n=106, 109 | -0.1 ± 0.33 | -1.1 ± 0.33 |
| HADS depression score; n=106, 108 | 0.0 ± 0.33 | -1.4 ± 0.32 |
The percentage of participants with a new diagnosis of PsA (ie, with an adverse event of PsA) during the study, among participants without PsA at Baseline.
| percentage of participants | Placebo | Adalimumab EOW |
|---|---|---|
| Percentage of Participants With a New Diagnosis of Psoriatic Arthritis (PsA) During the Study | 0 | 2 |
Participants were asked how their fingernail psoriasis impacted their overall quality of life over the past 7 days on an 11-point scale, with 0 indicating no impact, and 10 indicating severe impact. A negative change from Baseline indicates improvement.
| units on a scale | Placebo | Adalimumab EOW |
|---|---|---|
| Change From Baseline in Nail Psoriasis Quality of Life (Nail PsQoL) Score at Week 26 | -0.6 ± 0.23 | -3.3 ± 0.23 |
Collected over Adverse events were collected from Baseline through Week 52 +70 day follow up phone call; serious adverse events were collected from Screening through Week 52 + 70 day follow up call.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Period A) | — | 5/108 (4.6%) | 43/108 (39.8%) |
| Adalimumab EOW (Period A) | — | 8/109 (7.3%) | 45/109 (41.3%) |
| Placebo/Adalimumab EOW (Period B) | — | 3/94 (3.2%) | 28/94 (29.8%) |
| Adalimumab EOW/Adalimumab EOW (Period B) | — | 3/94 (3.2%) | 34/94 (36.2%) |
| Event | Placebo (Period A) | Adalimumab EOW (Period A) | Placebo/Adalimumab EOW (Period B) | Adalimumab EOW/Adalimumab EOW (Period B) |
|---|---|---|---|---|
| PNEUMONIAInfections and infestations | 2/108 | 0/109 | 0/94 | 1/94 |
| MYOCARDIAL INFARCTIONCardiac disorders | 0/108 | 0/109 | 1/94 | 0/94 |
| DIVERTICULITISInfections and infestations | 0/108 | 1/109 | 1/94 | 0/94 |
| INFLUENZAInfections and infestations | 0/108 | 0/109 | 0/94 | 1/94 |
| LUNG INFECTIONInfections and infestations | 0/108 | 0/109 | 1/94 | 0/94 |
| TENOSYNOVITISMusculoskeletal and connective tissue disorders | 0/108 | 0/109 | 0/94 | 1/94 |
| SEIZURENervous system disorders | 0/108 | 0/109 | 0/94 | 1/94 |
| BLADDER SPHINCTER ATONYRenal and urinary disorders | 0/108 | 0/109 | 0/94 | 1/94 |
| STRESS URINARY INCONTINENCERenal and urinary disorders | 0/108 | 0/109 | 0/94 | 1/94 |
| ATRIAL FIBRILLATIONCardiac disorders | 1/108 | 0/109 | 0/94 | 0/94 |
| Event | Placebo (Period A) | Adalimumab EOW (Period A) | Placebo/Adalimumab EOW (Period B) | Adalimumab EOW/Adalimumab EOW (Period B) |
|---|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 10/108 | 6/109 | 9/94 | 12/94 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 9/108 | 9/109 | 6/94 | 4/94 |
| PSORIASISSkin and subcutaneous tissue disorders | 6/108 | 1/109 | 4/94 | 1/94 |
| HEADACHENervous system disorders | 0/108 | 6/109 | 2/94 | 1/94 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 4/108 | 5/109 | 0/94 | 1/94 |
| BACK PAINMusculoskeletal and connective tissue disorders | 4/108 | 2/109 | 1/94 | 2/94 |
| GASTROENTERITISInfections and infestations | 1/108 | 4/109 | 3/94 | 2/94 |
| HYPERTENSIONVascular disorders | 2/108 | 4/109 | 0/94 | 1/94 |
| TOOTHACHEGastrointestinal disorders | 0/108 | 0/109 | 0/94 | 3/94 |
| BRONCHITISInfections and infestations | 0/108 | 2/109 | 3/94 | 2/94 |
| Age, Continuous(years) | Placebo | Adalimumab EOW | Total |
|---|---|---|---|
| Mean | 46.16 ± 12.134 | 47.21 ± 11.858 | 46.69 ± 11.980 |
| Age, Customized(participants) | Placebo | Adalimumab EOW | Total |
|---|---|---|---|
| < 40 years | 34 | 30 | 64 |
| 40 to ≤ 64 years | 65 | 70 | 135 |
| ≥ 65 years | 9 | 9 | 18 |
| Sex: Female, Male(Participants) | Placebo | Adalimumab EOW | Total |
|---|---|---|---|
| Female | 21 | 13 | 34 |
| Male | 87 | 96 | 183 |
No study locations are listed for this record.
The record gives a start of Jan 2014, a primary completion of Oct 2015 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab